For UK MedTech companies
Clinicians want your product. NHS procurement is why they still don't have it.
Capital approval in the NHS routinely involves five or more sign-off stages and resets with each financial year. Without a structured approach to procurement, sales teams burn through budget while the cycle repeats.
Two minutes. Solva follows up with specific market access options.
- Inefficient resource allocation within sales and market access teams
- Stalled product launch timelines
- Significant sales team burn rate (£30,000-£50,000 per month)
- Lost revenue from delayed market entry
- Delayed patient access to innovative treatments
- Suboptimal patient outcomes due to reliance on older technologies
- Perception of slow innovation and market responsiveness
- Difficulty attracting top talent due to market access challenges
MedTech companies with a structured procurement navigation approach close deals 40% faster than those relying on clinical advocacy alone. (CPI, 2025)
Source: CPI, 2025 (as cited in problem card, direct report not publicly accessible)
Frequently asked questions
Why does this problem persist?
Capital procurement in NHS and independent healthcare is genuinely slow. Companies that don't understand the process, build relationships with procurement teams, and structure their commercial model to reduce the budget barrier lose years to avoidable delays.
What is the cost of leaving it unaddressed?
Fragmented NHS procurement deters investors and delays patient access to innovation - and costs companies £30,000-£50,000 per month in sales team burn. (CPI, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.